Introduction
============

According to Global Cancer Statistics for 2018, gastric cancer (GC) is the fifth most prevalent cancer type and the third leading cause of cancer-associated mortality worldwide ([@b1-ol-0-0-11961]). Of note, its prevalence is markedly elevated in Eastern Asia. The number of newly diagnosed GC cases in 2018 was 1,033,701 worldwide and the estimated number of deaths was 782,685, translating to 1 in every 12 deaths globally ([@b1-ol-0-0-11961]). Risk factors commonly associated with GC include chronic infection with *Helicobacter pylori* (*H. pylori*), environmental factors, low fruit and vegetable intake, consumption of preserved foods, smoking and alcohol use ([@b2-ol-0-0-11961],[@b3-ol-0-0-11961]). At present, surgery and chemotherapy are the major therapeutic strategies used to treat GC ([@b4-ol-0-0-11961]). However, only a limited number of patients with GC are diagnosed at early stage, whereas the majority of patients are diagnosed at advanced stage ([@b5-ol-0-0-11961]). The 5-year overall survival (OS) rate for patients with GC was only 27.4% in China in 2010, and 29% in the United States in 2009 ([@b6-ol-0-0-11961],[@b7-ol-0-0-11961]). Therefore, it is important to explore the molecular mechanisms involved in the tumorigenesis and progression of GC, which may identify novel prognostic biomarkers and treatment targets.

The glutathione S-transferase Mu (GSTM) gene family consists of five genes identified in humans that are numbered M1-5. These genes occur as a cluster on chromosome 1p13, which are arranged in tandem, spanning a 97-kb region, and encode one of eight distinct classes of glutathione transferases ([@b8-ol-0-0-11961]--[@b10-ol-0-0-11961]). The GSTM gene family is arranged in a 5′-GSTM4-M2-M1-M5-M3-3′ sequence ([@b9-ol-0-0-11961]). These genes share a sequence homology of 60--80% ([@b11-ol-0-0-11961]). GSTM genes are generally recognized as detoxifying enzymes involved in the deactivating conversion of carcinogenic reactive metabolites, suggesting that these enzymes may have a role in carcinogenesis ([@b12-ol-0-0-11961]). To date, there is a lack of studies focusing on the value of the GSTM family of genes as prognostic biomarkers in GC.

To investigate the prognostic value and potential functions of GSTM genes in patients with GC, gene expression data and survival information from The Cancer Genome Atlas (TCGA) were analyzed. Subsequently, the Kaplan-Meier (KM) plotter online database was used to validate mRNA expression levels and the prognostic value of individual GSTM genes in patients with GC. Several bioinformatics tools were also used to explore the potential functions of GSTM genes.

Materials and methods
=====================

### Functional and co-expression analyses

To analyze the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment of GSTM genes, the Database for Annotation, Visualization and Integrated Discovery (DAVID) version 6.8; (<https://david.ncifcrf.gov/home.jsp>; accessed March 1, 2018) was used ([@b13-ol-0-0-11961],[@b14-ol-0-0-11961]). The functional examination based on GO includes the categories molecular function (MF), biological process (BP) and cellular component (CC). To evaluate gene-gene networks, the Gene Multiple Association Network Integration Algorithm (GeneMANIA) version 3.6.0 (<http://www.genemania.org>; accessed May 20, 2019), which predicted gene functions, was used ([@b15-ol-0-0-11961],[@b16-ol-0-0-11961]). The Search Tool for the Retrieval of Interacting Genes (STRING) version 11.0 (<https://string-db.org>; accessed May 20, 2019) database was used to search and analyze protein-protein interaction (PPI) networks ([@b17-ol-0-0-11961]).

### Co-expression matrix

A co-expression matrix of GSTM genes was constructed using mRNA expression data from TCGA cohort of GC tumor tissues. Pearson\'s correlation coefficient analysis was used to analyze mRNA co-expression correlations. The co-expression matrix was constructed using the corrplot package in the R 3.4.4 platform ([@b18-ol-0-0-11961]). P\<0.05 was considered to indicate a statistically significant difference.

### TCGA

RNA sequencing and clinical information (including tumor stage, age of patient and sex) linked with GC were downloaded from TCGA (<https://portal.gdc.cancer.gov>; accessed August 22, 2018). The TCGA data portal contained 407 patients diagnosed with GC, which included 375 tumor tissues and 32 adjacent normal tissues. After removing cases with missing follow-up profiles, a total of 351 patients with GC from TCGA were analyzed. Clinical data including clinical tumor-node-metastasis (TNM) stage ([@b19-ol-0-0-11961]), Lauren classification ([@b20-ol-0-0-11961]), differentiation grade, human epidermal growth factor receptor 2 (HER2) status and clinical treatment were also collected.

### Survival analysis

KM survival analyses and log-rank tests were used to calculate the OS rate and significance. Patients with GC were separated into high- and low-expression groups of GSTM based on the median values of expression. To perform univariate and multivariate survival analyses, the Cox proportional hazards regression model was used to calculate the hazard ratio (HR), 95% confidence interval (CI) and log-rank P-values. P\<0.05 was considered to indicate a statistically significant difference.

### KM plotter online database

The associations between the mRNA levels of individual GSTM genes and OS rates were calculated using the KM plotter online database (<http://kmplot.com/analysis/index.php?p=service&cancer=gastric>) ([@b21-ol-0-0-11961]) based on gene expression data and survival information of 875 patients with GC downloaded from the Gene Expression Omnibus (datasets GSE14210, GSE15459, GSE22377, GSE29272, GSE51105 and GSE62254) ([@b22-ol-0-0-11961]). This tool was used for the identification and validation of survival biomarkers. In brief, GSTM1-5 were entered into the KM plotter online database and analyzed. Based on the median of mRNA expression for each GSTM according to the Gene Expression Omnibus, all GC patients were separated into two groups (high vs. low). Statistical parameters such as survival plot, HRs, 95% CIs and log-rank P-values were obtained from KM plotter. P\<0.05 was considered to indicate a statistically significant difference.

### Nomogram and stratified analyses

Based on the survival analysis of TCGA and KM plotter, only GSTM5 was significantly associated with prognosis. A nomogram was developed and used to evaluate the contribution of GSTM5 expression and prognostic clinical parameters, including sex, age and tumor stage, in GC OS. Based on prognostic clinical indicators and the survival analysis of the Cox regression model, sex, age, stage and GSTM5 levels were entered into the risk model. The points against each factor were counted, and 1-, 3- and 5-year survival rates were also calculated ([@b23-ol-0-0-11961]). The nomogram was constructed using the rms package (<https://CRAN.R-project.org/package=rms>) ([@b24-ol-0-0-11961]).

To assess the prognostic value of GSTM5 in different GC strata, a stratified analysis method was performed. The association between GSTM5 and OS in TCGA and KM plotter online database were stratified in the GC cohort for sex, age, clinical stage, Lauren classification, differentiation grade, clinical treatment and HER2 status.

### Gene Set Enrichment Analysis (GSEA)

To investigate how the prognostic GSTM5 gene participates in GC, GSEA v.3.0 software (<http://software.broadinstitute.org/gsea/msigdb/index.jsp>) was used to identify the potential biological functions and signaling pathways associated with low vs. high expression levels of GSTM5. The Molecular Signatures Database of GSEA used the c2 (c2.cp.kegg.v6.2.symbols.gmt) and c5 (c5.all.v6.2.symbols.gmt) reference gene sets ([@b25-ol-0-0-11961]). A value of 1,000 was set as the number of permutations. P\<0.05, normalized enrichment score \>1 and false discovery rate \<0.25 were considered to indicate a statistically significant difference.

### Genome-wide co-expression analysis of the prognostic GSTM5 gene and functional enrichment

To assess gene-gene co-expression interaction of prognostic genes at the mRNA level, Pearson\'s correlation coefficient was calculated using the cor function on the R 3.4.4 platform. Significant differences were defined as \|r\|\>0.6 and P\<0.05. In addition, DAVID version 6.8 was used to determine the GO functional term and KEGG pathway enrichment of GSTM and its co-expressed genes.

### Statistical analyses

All data were analyzed using SPSS version 25.0 software (IBM, Corp.). Vertical scatterplots and survival curves were generated using GraphPad Prism 7.0 software (GraphPad Software, Inc.). Vertical scatterplots were analyzed using independent t-tests. In addition, nomograms and correlation plots were generated using R software.

Results
=======

### GSTM family functional enrichment and co-expression analysis

To evaluate the biological functions of GSTM genes, GO functional terms were determined in the categories BP, MF and CC and a KEGG pathway analysis was performed using DAVID ([Fig. 1](#f1-ol-0-0-11961){ref-type="fig"}). GO analysis indicated that genes of the GSTM family were enriched in 'protein homodimerization activity', 'enzyme binding' and in the 'cytosol' ([Fig. 1A](#f1-ol-0-0-11961){ref-type="fig"}). The results from the KEGG analysis suggested that the functions of the GSTM gene family were enriched in 'chemical carcinogenesis', 'metabolism of xenobiotics by cytochrome P450' and 'drug metabolism-cytochrome P450' ([Fig. 1B](#f1-ol-0-0-11961){ref-type="fig"}). Gene-gene interaction networks of GSTM genes are presented in [Fig. 2A](#f2-ol-0-0-11961){ref-type="fig"}, which revealed that GSTM1-5 were co-expressed. In addition, the GSTM genes were associated with other genes with the relationship of predicted interactions, physical interactions, co-expression, and shared pathway. Based on the information in the STRING database, PPI interaction networks revealed that GSTM family members were directly and indirectly connected to one another ([Fig. 2B](#f2-ol-0-0-11961){ref-type="fig"}). The PPI network revealed that GSTM1 was only associated with GSTM2, and GSTM2 was the only gene that associated with all other family members. In addition, co-expression of the GSTM genes was observed in GC tissues, although the correlation coefficients appear to be weak (\<0.4) ([Fig. 3](#f3-ol-0-0-11961){ref-type="fig"}).

### Survival analysis

Significant differences were obtained in the vertical scatterplots between high and low expression of GSTM genes obtained from TCGA (all P\<0.001; [Fig. 4](#f4-ol-0-0-11961){ref-type="fig"}). A survival analysis comparing patients with GC with different expression levels of GSTM is presented in [Fig. 5](#f5-ol-0-0-11961){ref-type="fig"}. High GSTM5 expression was significantly associated with a worse prognosis for patients with GC (HR=1.47, 95% CI: 1.06-2.04, P=0.021). A significant association between high GSTM4 expression and favorable OS was observed (HR=0.63, 95% CI: 0.45-0.87, P=0.006).

Multivariate survival analysis was also performed to investigate the prognostic value of GSTM in GC. Age and tumor stage were two factors identified to be significantly associated with prognosis, as an age of ≥65 years and advanced stages were significantly associated with a worse OS (HR=1.56, 95% CI: 1.12-2.17, P=0.011; HR=1.92, 95% CI: 1.37-2.70, P\<0.001, respectively; [Table I](#tI-ol-0-0-11961){ref-type="table"}). To examine survival, tumor stage and age were analyzed using the multivariate Cox proportional hazards regression model. These analyses revealed that high GSTM5 expression was significantly associated with worse OS (HR=1.48, 95% CI: 1.05-2.08, adjusted P=0.027; [Table II](#tII-ol-0-0-11961){ref-type="table"}). These results were consistent with those of the univariate survival analysis ([Table II](#tII-ol-0-0-11961){ref-type="table"}). However, no significant differences were identified for GSTM4 in the multivariate survival analysis ([Table II](#tII-ol-0-0-11961){ref-type="table"}), which was not consistent with the results obtained in the univariate survival analysis (HR=0.63, 95% CI: 0.45-0.87, P=0.006; [Table II](#tII-ol-0-0-11961){ref-type="table"} and [Fig. 5D](#f5-ol-0-0-11961){ref-type="fig"}).

### Validation of the GSTM cohort using the KM plotter online database

The GSTM cohort was validated using the KM plotter online database. KM curves of GSTM genes are presented in [Fig. 6](#f6-ol-0-0-11961){ref-type="fig"}. These analyses revealed that high GSTM1, GSTM2, GSTM4 and GSTM5 mRNA levels were associated with a significantly worse OS for patients with GC (HR=1.44, 95% CI: 1.21-1.71, P=2.6×10^−5^; HR=1.57, 95% CI: 1.32-1.86, P=2×10^−7^; HR=1.23, 95% CI: 1.04-1.46, P=0.015; and HR=1.69, 95% CI: 1.42-2.01, P=1.6×10^−9^, respectively). The only result consistent with the TCGA analyses was that GSTM5 was significantly associated with a worse prognosis (HR=1.47, 95% CI: 1.06-2.04, P=0.021; [Table II](#tII-ol-0-0-11961){ref-type="table"} and [Fig. 5E](#f5-ol-0-0-11961){ref-type="fig"}).

### Nomogram and stratified analysis

A nomogram for GC was developed based on GSTM5 expression levels, sex, age, tumor stage and 1-, 3- and 5-year survival rate ([Fig. 7](#f7-ol-0-0-11961){ref-type="fig"}). The 1-, 3- and 5-year survival rates were higher for patients with a lower number of total points compared with those with a higher number of total points. In accordance with the nomogram, it was observed that the contribution of GSTM5 expression in prognosis prediction was lower compared with that of age and tumor stage, but higher compared with that of sex. The nomogram analyses revealed that GSTM5 contributes to the prognosis prediction for patients with GC. In addition, the prognostic value of GSTM5 in GC was analyzed using stratification analysis and the association between GSTM5 and OS was analyzed using the TCGA ([Table III](#tIII-ol-0-0-11961){ref-type="table"}) and KM plotter online database ([Table IV](#tIV-ol-0-0-11961){ref-type="table"}) GC cohorts, which included analyses for sex, age, clinical stage, Lauren classification, differentiation grade, clinical treatment and HER2 status. As presented in [Table III](#tIII-ol-0-0-11961){ref-type="table"}, high GSTM5 mRNA levels were significantly associated with poor prognosis in patients with GC who were males and \<65 years old based on the TCGA GC cohort (HR=1.59, 95% CI: 1.07-2.36, P=0.020; HR=1.86, 95% CI: 1.07-3.25, P=0.030, respectively). As presented in [Table IV](#tIV-ol-0-0-11961){ref-type="table"}, high GSTM5 mRNA levels were significantly associated with worse survival for both female and male patients with GC, clinical stages I, II and III, all Lauren classifications, treatment by surgery and other adjuvant therapies, as well as a negative HER2 status, according to the KM plotter analysis.

### GSEA analysis of GSTM5 in GC cases

To explore the mechanisms underlying GSTM5 function, GSEA was used to assess differences in relative GSTM5 expression levels among TCGA specimens ([Fig. 8](#f8-ol-0-0-11961){ref-type="fig"}, [Tables SI](#SD1-ol-0-0-11961){ref-type="supplementary-material"} and [SII](#SD1-ol-0-0-11961){ref-type="supplementary-material"}). In the GSEA, high levels of GSTM5 were significantly enriched in the following processes: 'regulation of cell matrix adhesion' (P\<0.001), 'angiogenesis' (P\<0.001), 'regulation of cell growth' (P\<0.001), 'regulation of endothelial cell apoptotic process' (P=0.004), 'extracellular matrix' (P\<0.001), 'smoothened signaling pathway' (P\<0.001), 'Hedgehog signaling pathway' (P\<0.001), 'mitogen-activated protein kinases (MAPK) signaling pathway' (P\<0.001), 'transforming growth factor (TGF)-β signaling pathway' (P=0.025), 'calcium signaling pathway' (P\<0.001) and other KEGG pathways associated with cancer.

### Genome-wide co-expression analysis of GSTM5 in GC and potential functional enrichment

To determine the potential mechanism underlying GSTM5 function in GC, genome-wide co-expression analysis was performed. Regulatory networks of GSTM5 and its co-expressed correlated genes identified in GC tumor tissues from the TCGA cohort are presented in [Fig. 9](#f9-ol-0-0-11961){ref-type="fig"} and [Table SIII](#SD1-ol-0-0-11961){ref-type="supplementary-material"}. GO analysis suggested that GSTM5 and its co-expressed genes were significantly enriched in processes including 'cell adhesion' (P=1.97×10^−5^), 'single organismal cell-cell adhesion' (P=3.83×10^−5^), 'focal adhesion' (P=3.24×10^−4^), 'positive regulation of cell-substrate adhesion' (P=0.003), 'angiogenesis' (P=0.004), 'apoptotic process involved in luteolysis' (P=0.048), 'negative regulation of cell growth' (P=2.75×10^−5^), 'negative regulation of cell proliferation' (P=8.51×10^−5^), 'negative regulation of cell migration' (P=8.89×10^−4^) and 'negative regulation of Wnt signaling pathway' (P=0.010). Enrichment of GSTM5 and its co-expressed genes in the 'plasma membrane' (P=0.002) and 'extracellular matrix' (P=1.88×10^−10^) was observed by GO cell component analysis ([Tables V](#tV-ol-0-0-11961){ref-type="table"} and [SIV](#SD1-ol-0-0-11961){ref-type="supplementary-material"}). Furthermore, GSTM5 and its co-expressed genes were enriched in the following KEGG pathways associated with prognosis: 'Cyclic guanosine monophosphate-protein kinase G (cGMP-PKG) signaling pathway' (P=3.04×10^−9^), cyclic adenosine monophosphate (cAMP) signaling pathway' (P=0.004), 'calcium signaling pathway' (P=0.008), 'focal adhesion' (P=0.017) and 'cell adhesion molecules (CAMs)' (P=0.026) ([Table VI](#tVI-ol-0-0-11961){ref-type="table"}).

Discussion
==========

In the present study, the expression levels of GSTM genes and their prognostic value in GC were assessed. A positive correlation was observed between GSTM5 expression and poor OS in GC. In addition, GSEA analysis and genome-wide co-expression analysis were used to predict potential mechanistic roles of GSTM5 in GC.

There are five members of the GSTM class of genes that encode phase II metabolic enzymes found primarily in the cytosol that co-operate with phase I enzymes in carcinogen metabolism ([@b26-ol-0-0-11961]). These genes are involved in the detoxification of electrophilic compounds, including carcinogens, therapeutic drugs, environmental toxins and products of oxidative stress, by conjugation with glutathione ([@b27-ol-0-0-11961]).

Previous studies revealed that the GSTM family of genes have critical roles in several cancer types. GSTM1 is highly polymorphic in humans and is associated with multiple cancer types, such as bladder and breast cancer, metabolic disorders and autoimmune diseases, as well as anticancer drugs response and resistance ([@b28-ol-0-0-11961]) GSTM1 deletion in humans was indicated to have a key role in bladder ([@b29-ol-0-0-11961]) and breast cancer ([@b30-ol-0-0-11961],[@b31-ol-0-0-11961]), multiple sclerosis ([@b32-ol-0-0-11961]), severe early-onset mental disorders including schizophrenia-spectrum disorder, bipolar disorder with psychotic symptoms or first-episode psychosis ([@b33-ol-0-0-11961]) and acute myeloid leukemia ([@b34-ol-0-0-11961]). Csejtei *et al* ([@b35-ol-0-0-11961]) identified that GSTM1 may be a prognostic biomarker in clinical diagnostics as well as a potential therapeutic candidate in colorectal cancer. A recent study detected null GSTM1 genotypes in the tumor area of GC, in contrast to the presence of both genes in the proximal and distal margins of the tumor ([@b36-ol-0-0-11961]). Therefore, GSTM1 polymorphisms may be a potential prognostic marker for certain types of cancer. A protective effect of GSTM2 on oxidative stress was identified in studies performed in hepatic carcinoma, colon cells and spontaneously hypertensive rat ([@b37-ol-0-0-11961]--[@b39-ol-0-0-11961]). Previous studies have revealed an association between GSTM3 and certain cancer types, including laryngeal ([@b40-ol-0-0-11961]), oral ([@b41-ol-0-0-11961],[@b42-ol-0-0-11961]), esophageal ([@b43-ol-0-0-11961]), breast ([@b44-ol-0-0-11961]), bladder ([@b45-ol-0-0-11961]), multiple cutaneous basal cell ([@b46-ol-0-0-11961]) cancer and childhood acute lymphoblastic leukemia ([@b12-ol-0-0-11961]). GSTM4 is a less studied member of the GSTM family and has been demonstrated to recognize the same standard glutathione S-transferases substrate 1-chloro-2,4-dinitrobenzen as other GSTMs, only with lower specific activity ([@b47-ol-0-0-11961]). The possible role of GSTM5 in the development of cancer warrants further exploration. Peng *et al* ([@b48-ol-0-0-11961]) reported that GSTM5 is involved in the detoxification of reactive electrophiles and is associated with Barrett\'s adenocarcinoma. Pankratz *et al* ([@b49-ol-0-0-11961]) observed that high-risk tag single-nucleotide polymorphisms in GSTM5 and ATP binding cassette subfamily C member 4 genes may be a good combined predictor of mortality in low-stage non-small cell lung cancer. Gene-based analysis also revealed that the expression of GSTM5 was involved in the OS of patients diagnosed with low-stage non-small cell lung cancer ([@b49-ol-0-0-11961]). Similar results were observed in a study by Kap *et al* ([@b50-ol-0-0-11961]), reporting that GSTM5 was differentially expressed in colon cancer tissues compared with normal colon tissues. In addition, high expression of GSTM5 is associated with poor OS in patients with colorectal cancer treated with oxaliplatin (HR=1.50, 95% CI: 1.03-2.19) ([@b50-ol-0-0-11961]). These conclusions suggested that GSTM5 may be an important prognostic biomarker. Despite previous studies revealing an association between GSTM5 and OS, associations between GSTM5 and survival of patients with GC have remained to be determined. The present study revealed that among all GSTM genes, only GSTM5 was independently associated with poor OS in patients with GC. According to the present nomogram, it was indicated that the contribution of the tumor stage increased with more advanced stages and higher expression levels of GSTM5 were associated with a less favorable survival prognosis. Compared with the tumor stage, age, sex and GSTM5 expression, the tumor stage and age were more significantly associated with GSTM5 expression. Therefore, the OS rate of patients with GC may be predicted using this model. The nomogram indicated that the combination of GSTM5 and other indicators may be considered a novel method to predict the prognosis for patients with GC.

In the stratified analyses with the KM plotter online database, higher levels of GSTM5 were associated with worse OS in female and male patients, clinical stages I--III, all Lauren classifications, treatment by surgery, administration of other adjuvant therapies, as well as a negative HER2 status. However, OS was not associated with female sex, age \>65 years or clinical stage in the TCGA GC cohort. There were 375 cases of GC in the TCGA, but there were 875 cases of GC in the KM plotter online database. As TCGA appeared to have a shortage of GC samples, another prospective study should be performed in the future. The comprehensive survival analysis with stratification suggested that GSTM5 has value as an independent prognostic indicator for GC.

The mechanisms underlying the functions of GSTM5 in GC have remained largely elusive. In the present study, the outcomes of the GSEA analysis indicated that GSTM5 is involved in 'regulation of cell matrix adhesion', 'angiogenesis', 'regulation of cell growth', 'regulation of endothelial cell apoptotic process', 'Hedgehog signaling', 'MAPK signaling', 'TGF-β signaling' and other cancer-associated pathways. According to the results of the genome-wide co-expression matrix, co-expressed genes were enriched in 'cell adhesion', 'angiogenesis', 'apoptotic process involved in luteolysis', 'cGMP-PKG signaling pathway' and 'cAMP signaling pathway'. In the GSEA analysis as well as the genome-wide co-expression matrix, enrichment in adhesion, angiogenesis and apoptosis was determined. During tumorigenesis, recurrence, invasion and metastasis are significantly affected by adhesion molecules ([@b48-ol-0-0-11961]). Aberrant expression of cell adhesion molecules may lead to abnormal proliferation of normal cells, and aberrant expression of these molecules is frequently associated with general carcinogenesis ([@b51-ol-0-0-11961]). Angiogenesis allows the tumor to grow, infiltrate and metastasize ([@b52-ol-0-0-11961]). Du *et al* ([@b53-ol-0-0-11961]) demonstrated that the synthesis of vascular endothelial growth factor is modulated by the cAMP-protein kinase A-cAMP response element-binding pathway. Zhang *et al* ([@b54-ol-0-0-11961]) reported that loss of the regulative effect of dimethylarginine dimethylaminohydrolase 1 in the nitric oxide-cGMP-PKG pathway may lead to decreased angiogenesis. These studies demonstrated that cAMP and cGMP biosynthesis are associated with angiogenesis.

The Hedgehog pathway serves a crucial role in cell proliferation and differentiation in adult organisms, and dysregulation of this pathway is associated with multiple cancer types. Saze *et al* ([@b55-ol-0-0-11961]) demonstrated that Hedgehog signaling is a prognostic indicator for patients with GC. Qin *et al* ([@b56-ol-0-0-11961]) revealed that Hedgehog signaling is associated with the apoptosis of GC cells. The MAPK signaling pathway serves a vital role in controlling cellular processes, including proliferation, differentiation and apoptosis ([@b57-ol-0-0-11961]). As a multifunctional growth factor, TGF-β regulates several cellular processes, including proliferation, development, homeostasis of stem cells, enhancing fibrosis and modulating the immune response through its downstream targets ([@b58-ol-0-0-11961]). TGF family of proteins are involved in tumor initiation and progression, cell proliferation, angiogenesis, epithelial to mesenchymal transition, invasion and inflammation ([@b59-ol-0-0-11961]). The results of the present GSEA analysis and genome-wide co-expression matrix demonstrated that high expression of GSTM5 was associated with the prognosis of GC. However, the exact mechanisms underlying the function of GSTM5 in the development of GC require to be elucidated.

The present study has certain limitations. First, since the clinical parameters were obtained from a public database, some clinical data were not available such as chemotherapy, smoking and infection with *Helicobacter pylori*, and therefore, a comprehensive analysis was not performed. Furthermore, the results were obtained with the dataset of the public TCGA database. Therefore, further experiments such as immunohistochemistry for GSTM5 should be designed and performed to validate the prognostic value in GC. In addition, the association between GSTM proteins and GC prognosis was not investigated, since GSTM protein expression data were not available. Despite these limitations, the present study was the first to systematically investigate the association between the expression of GSTM genes and OS in GC, to the best of our knowledge. The present results indicated that high expression of GSTM5 in GC is associated with poor prognosis, suggesting that GSTM5 may be a novel prognostic indicator for GC.

In conclusion, the present study indicated that GSTM5 mRNA expression is associated with unfavorable OS in patients with GC. This suggests that GSTM5 may be a prognostic marker and potential target for GC therapy. Furthermore, the potential mechanisms underlying GSTM5 function in GC were also explored using the GSEA and genome-wide co-expression analyses. To predict the OS of patients with GC, a nomogram composed of GSTM5 and tumor stage was also constructed. However, additional studies are required to further validate the results of the present study.
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![Gene set enrichment analysis results of c2 and c5 reference gene sets for higher expression of GSTM5 in gastric cancer tissues. (A) Regulation of cell matrix adhesion. (B) Cell-cell adhesion via plasma membrane adhesion molecules. (C) Angiogenesis. (D) Regulation of cell growth. (E) Negative regulation of cell growth. (F) Regulation of endothelial cell apoptotic process. (G) Negative regulation of leukocyte apoptotic process. (H) Extracellular matrix. (I) Extracellular matrix component. (J) Smoothened signaling pathway. (K) Cell adhesion molecule. (L) Hedgehog signaling pathway. (M) MAPK signaling pathway. (N) TGF-β signaling pathway. (O) Calcium signaling pathway. (P) Pathways in cancer. GSTM, glutathione S-transferase Mu; MAPK, mitogen-activated protein kinase; TGF, transforming growth factor; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; NES, normalized enrichment score; NOM, nominal; FDR, false discovery rate.](ol-20-04-11961-g07){#f8-ol-0-0-11961}

![Regulation network of GSTM5 and its co-expressed genes in gastric cancer tumor tissue in The Cancer Genome Atlas cohort. GSTM5, glutathione S-transferase Mu 5.](ol-20-04-11961-g08){#f9-ol-0-0-11961}

###### 

Demographic and clinical data in The Cancer Genome Atlas gastric cancer cohort (n=351).

  Variable              N     Events, n (%)   MST, days   HR (95% CI)        Log-rank P-value
  --------------------- ----- --------------- ----------- ------------------ ------------------
  Sex                                                                        0.152
    Male                226   99 (43.8)       869         Ref.               
    Female              125   44 (35.2)       1,043       0.77 (0.55-1.09)   
  Age (years)                                                                0.011
    \<65                148   50 (33.8)       1,811       Ref.               
    ≥65                 197   92 (46.7)       779         1.56 (1.12-2.17)   
    NA                  6                                                    
  Tumor stage                                                                \<0.001
    Early (I+II)        156   44 (28.2)       1,811       Ref.               
    Advanced (III+IV)   180   89 (49.4)       675         1.92 (1.37-2.70)   
    NA                  15                                                   
  Tumor stage                                                                \<0.001
    I                   47    11 (23.4)       2,197       Ref.               
    II                  109   33 (30.3)       1,686       1.55 (0.78-3.08)   
    III                 145   67 (46.2)       782         2.38 (1.26-4.51)   
    IV                  35    22 (62.9)       476         3.81 (1.85-7.86)   
    NA                  15                                                   

MST, median survival time; HR, hazard ratio; Ref., reference; NA, not available.

###### 

Analysis of the association between GSTM genes and the risk of death in The Cancer Genome Atlas gastric cancer cohort (n=351).

  Gene expression status   Median expression   N     Events, n (%)   MST, days   Crude HR (95% CI)   Crude P-value   Adjusted HR^[a](#tfn2-ol-0-0-11961){ref-type="table-fn"}^ (95% CI)   Adjusted P-value ^[a](#tfn2-ol-0-0-11961){ref-type="table-fn"}^
  ------------------------ ------------------- ----- --------------- ----------- ------------------- --------------- -------------------------------------------------------------------- -----------------------------------------------------------------
  GSTM1                    36.0                                                                      0.544                                                                                0.877
    Low                                        176   68 (38.6)       869         Ref.                                Ref.                                                                 
    High                                       175   75 (42.9)       1,095       1.11 (0.80-1.54)                    0.97 (0.69-1.38)                                                     
  GSTM2                    349.7                                                                     0.257                                                                                0.263
    Low                                        176   66 (37.5)       2,100       Ref.                                Ref.                                                                 
    High                                       175   77 (44.0)       869         1.2 (0.87-1.68)                     1.22 (0.86-1.71)                                                     
  GSTM3                    2105.3                                                                    0.391                                                                                0.247
    Low                                        176   70 (39.8)       881         Ref.                                Ref.                                                                 
    High                                       175   73 (41.7)       940         1.15 (0.83-1.60)                    1.23 (0.87-1.74)                                                     
  GSTM4                    2570.1                                                                    0.006                                                                                0.067
    Low                                        176   84 (47.7)       712         Ref.                                Ref.                                                                 
    High                                       175   59 (33.7)       1,686       0.63 (0.45-0.87)                    0.72 (0.50-1.02)                                                     
  GSTM5                    107.5                                                                     0.021                                                                                0.027
    Low                                        176   64 (36.4)       1,153       Ref.                                Ref.                                                                 
    High                                       175   79 (45.9)       794         1.47 (1.06-2.04)                    1.48 (1.05-2.08)                                                     

Adjusted for age and tumor stage. GSTM, glutathione S-transferase Mu; MST, median survival time; HR, hazard ratio; Ref., reference.

###### 

Stratified analysis of the association between GSTM5 expression levels and overall survival in The Cancer Genome Atlas gastric cancer cohort (n=351).

  Variable     Total, n   Low GSTM5, n   High GSTM5, n   HR (95% CI)         Log-rank P-value
  ------------ ---------- -------------- --------------- ------------------- ------------------
  Sex                                                                        
    Male       226        113            113             1.59 (1.07-2.36)    0.020
    Female     125        63             62              1.06 (0.58-1.91)    0.860
  Age, years                                                                 
    \<65       148        74             74              1.86 (1.07-3.25)    0.030
    ≥65        197        99             98              1.11 (0.74-1.688)   0.603
    NA         6                                                             
  Stage                                                                      
    Early      156        78             78              1.48 (0.82-2.68)    0.189
    Advanced   180        90             90              1.34 (0.88-2.04)    0.164
    NA         15                                                            
  Stage                                                                      
    I          47         24             23              1.31 (0.40-4.29)    0.651
    II         109        55             54              1.52 (0.77-3.02)    0.217
    III        145        73             72              1.49 (0.92-2.42)    0.098
    IV         35         18             17              1.15 (0.49-2.68)    0.744
    NA         15                                                            

GSTM5, glutathione S-transferase Mu 5; HR, hazard ratio; NA, not available.

###### 

Stratified analysis of the association between GSTM5 expression levels and overall survival in the Kaplan-Meier plotter gastric cancer cohort (n=875).

  Variable                Total, n   Low GSTM5, n   High GSTM5, n   HR (95% CI)         Log-rank P-value
  ----------------------- ---------- -------------- --------------- ------------------- ------------------
  Sex                                                                                   
    Female                236        120            116             1.87 (1.31-2.68)    \<0.001
    Male                  544        275            269             1.84 (1.48-2.29)    2.4×10^−8^
    NA                    95                                                            
  Stage                                                                                 
    I                     67         34             33              3.02 (0.96-9.55)    0.048
    II                    140        71             69              2.20 (1.17-4.15)    0.012
    III                   305        152            153             1.47 (1.11-1.96)    0.008
    IV                    148        74             74              1.41 (0.96-2.08)    0.075
    NA                    215                                                           
  Lauren classification                                                                 
    Intestinal            320        161            159             2.42 (1.74-3.36)    7.1×10^−8^
    Diffuse               241        121            120             1.95 (1.37-2.76)    \<0.001
    Mixed                 32         16             16              4.26 (1.34-13.55)   0.007
    NA                    282                                                           
  Differentiation                                                                       
    Poor                  165        82             83              0.71 (0.47-1.05)    0.085
    Moderate              67         34             33              1.01 (0.52-1.94)    0.978
    Well                  32         16             16              2.04 (0.84-4.94)    0.106
    NA                    611                                                           
  Treatment                                                                             
    Surgery alone         380        190            190             1.81 (1.35-2.43)    5.9×10^−5^
    5-Fu based adjuvant   152        76             76              0.86 (0.61-1.22)    0.389
    Other adjuvant        76         38             38              7.37 (2.15-25.21)   \<0.001
    NA                    267                                                           
  HER2 status                                                                           
    Negative              532        266            266             1.93 (1.53-2.44)    1.3×10^−8^
    Positive              343        172            171             1.22 (0.94-1.58)    0.139

GSTM5, glutathione S-transferase Mu 5; HR, hazard ratio; NA, not available; HER2, human epidermal growth factor receptor 2; 5-Fu, fluorouracil.

###### 

GO term enrichments of co-expressed genes of glutathione S-transferase Mu 5 in gastric cancer.

  Term                                                         Count   P-value        Genes
  ------------------------------------------------------------ ------- -------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  GO:0007155\~cell adhesion                                    22      1.97×10^−5^    SELP, SVEP1, CYP1B1, ATP1B2, MPDZ, IGFBP7, MCAM, EMILIN1, ITGA9, PGM5, SRPX, S1PR1, COL19A1, ITGA7, RHOB, TGFB1I1, MFAP4, BOC, PARVA, FEZ1, AOC3, SPON1
  GO:0016337\~single organismal cell-cell adhesion             10      3.83×10^−5^    COL14A1, LIMS2, COL19A1, FOXF1, PIP5K1C, NLGN2, JAM2, COL8A2, NTN1, NEGR1
  GO:0005925\~focal adhesion                                   18      3.24×10^−4^    TLN1, LIMS2, PDLIM7, FHL1, FERMT2, PIP5K1C, CSRP1, MCAM, FLNA, ANXA6, TNS2, TNS1, PGM5, LAYN, ILK, RHOB, TGFB1I1, PARVA
  GO:0010811\~positive regulation of cell-substrate adhesion   5       0.003          SMOC2, FOXF1, CCDC80, ABI3BP, EMILIN1
  GO:0001525\~angiogenesis                                     11      0.004          CYP1B1, S1PR1, MEOX2, RHOB, TMEM100, TNFSF12, MCAM, COL8A2, MEIS1, JAM3, MMRN2
  GO:0061364\~apoptotic process involved in luteolysis         2       0.048          SLIT2, SLIT3
  GO:0031012\~extracellular matrix                             25      1.88×10^−10^   LTBP1, IGFBP7, DCN, ABI3BP, MMRN2, OGN, ILK, COL8A2, MYOC, SPON1, MGP, CPXM2, SOD3, FLNA, EMILIN1, PRELP, FBLN1, COL14A1, SERPINF1, SFRP1, FBLN5, TGFB1I1, MFAP4, SSC5D, CLEC14A
  GO:0030198\~extracellular matrix organization                18      2.11×10^−8^    RECK, ELN, CCDC80, DCN, ABI3BP, EMILIN1, ITGA9, SMOC2, FBLN1, COL14A1, COL19A1, CRISPLD2, FOXF1, FBLN5, ITGA7, JAM2, JAM3, COL8A2
  GO:0005578\~proteinaceous extracellular matrix               21      2.62×10^−8^    LTBP1, PODN, SPARCL1, ADAMTSL3, ELN, MGP, SLIT2, PRELP, SLIT3, EMILIN1, OGN, SMOC2, FBLN1, COL14A1, COL19A1, SFRP1, CRISPLD2, FBLN5, COL8A2, MYOC, SPON1
  GO:0005576\~extracellular region                             52      6.02×10^−6^    NXPH3, TLN1, A2M, LTBP1, FGF7, CXORF36, IGFBP7, TNFSF12, OLFML1, OGN, ST3GAL3, RSPO1, RSPO3, ITIH5, LGI4, GHR, SERPING1, SLIT2, FLNA, SLIT3, PRELP, CHRDL1, PTGDS, SERPINF1, MFAP4, ELN, C1R, DCN, C1S, C1QTNF7, METTL24, ANGPTL7, IL17B, CRISPLD2, COL8A2, VSTM4, SVEP1, EFEMP2, PTGFR, FRZB, NTN1, SOD3, PLAC9, EMILIN1, FBLN1, COL14A1, COL19A1, CCL14, SFRP1, FAM198A, LCN6, FBLN5
  GO:0005201\~extracellular matrix structural constituent      8       1.02×10^−4^    FBLN1, COL14A1, COL19A1, EFEMP2, ELN, MGP, COL8A2, PRELP
  GO:0050840\~extracellular matrix binding                     4       0.008          SPARCL1, ELN, DCN, SSC5D
  GO:0005886\~plasma membrane                                  92      0.002          RHOJ, SLC9A9, GYPC, CADM3, TLN1, JPH2, ATP1B2, TACR2, ADCY5, GRIK5, NCS1, TNFSF12, FRRS1L, DMPK, EDNRA, ST6GALNAC6, S1PR1, SLC2A4, NMUR1, ILK, GUCY1A3, RHOB, ATP8B2, TMEM100, FAM129A, NEGR1, BOC, GHR, RAMP3, KCNMA1, RECK, AR, MAGI2, ACKR1, MRGPRF, COLEC12, FLNA, SLIT2, TNS2, CHRM2, ROR2, GUCY1B3, CLIP3, JAM2, JAM3, AOC3, PARVA, FXYD1, ABCA8, LIMS2, CYSLTR1, ARHGEF25, FHL1, GNG11, KCNA5, PLPP1, FXYD6, KCNMB1, RGMA, FAT3, PLIN4, PKD2, KLHL41, PRIMA1, EHD2, TRPC1, SELP, VSTM4, GNAO1, KLF9, EPM2A, MAP1B, NPR1, NPR2, ATP1A2, MAPK10, MCAM, PTGFR, ITPR1, ITGA9, ABCC9, TMEM47, PDE2A, SFRP1, PLSCR4, P2RY14, BNC2, ITGA7, SCN4B, APBB1, HTR2A, FEZ1
  GO:0030308\~negative regulation of cell growth               11      2.75×10^−5^    RERG, SFRP1, DACT3, CRYAB, FHL1, NPR1, WFDC1, FRZB, APBB1, SLIT2, SLIT3
  GO:0008285\~negative regulation of cell proliferation        19      8.51×10^−5^    AR, MAGI2, CYP1B1, PODN, ADARB1, NDN, IGFBP7, ZEB1, FRZB, PLPP1, KANK2, SLIT3, RERG, TNS2, SFRP1, SPEG, PKD2, ROR2, TGFB1I1
  GO:0030336\~negative regulation of cell migration            8       8.89×10^−4^    RECK, ADARB1, PODN, CYP1B1, MAGI2, SFRP1, RHOB, SLIT2
  GO:0030178\~negative regulation of Wnt signaling pathway     5       0.010          BARX1, SFRP1, DACT3, NFATC4, FRZB
  GO:0035385\~roundabout signaling pathway                     3       0.016          OGN, SLIT2, SLIT3
  GO:0007229\~integrin-mediated signaling pathway              6       0.022          ITGA9, FBLN1, FERMT2, ITGA7, ILK, ADAM33
  GO:0007224\~smoothened signaling pathway                     5       0.026          EVC, FOXF1, CC2D2A, ROR2, BOC

GO, gene ontology.

###### 

Kyoto Encyclopedia of Genes and Genomes term enrichments of co-expressed genes of glutathione S-transferase Mu 5 in gastric cancer.

  Term                                       Count   P-value       Genes
  ------------------------------------------ ------- ------------- ---------------------------------------------------------------------------------------------------------------------------
  hsa04022: cGMP-PKG signaling pathway       17      3.04×10^−9^   KCNMA1, ATP1B2, ADCY5, MRVI1, NPR1, NPR2, ATP1A2, KCNMB1, ITPR1, MYL9, EDNRA, PDE2A, PLN, PDE5A, GUCY1A3, NFATC4, GUCY1B3
  hsa04024: cAMP signaling pathway           10      0.004         EDNRA, FXYD1, ATP1B2, CHRM2, ADCY5, PLN, NPR1, MAPK10, ATP1A2, MYL9
  hsa04020: Calcium signaling pathway        9       0.008         EDNRA, CYSLTR1, TACR2, CHRM2, PLN, PDE1A, PTGFR, ITPR1, HTR2A
  hsa04510: Focal adhesion                   9       0.017         ITGA9, TLN1, ITGA7, ILK, PPP1R12C, MAPK10, FLNA, PARVA, MYL9
  hsa04514: Cell adhesion molecules (CAMs)   7       0.026         ITGA9, SELP, CADM3, NLGN2, JAM2, NEGR1, JAM3

Hsa, *Homo sapiens*.

[^1]: Contributed equally
